About SanReno
SanReno is a Healthcare company based in Shanghai (China) founded in 2021, and was acquired by Novartis in January 2024. Therapies for kidney diseases are developed by SanReno. Its chief executive, as recorded, is Haoyu Huang. Its focus areas include Life Sciences, Nephrology, Drugs and Chronic Kidney Diseases.
Company details
SanReno was founded in 2021 and is based in Shanghai, China. Operations center on biotechnology, with emphasis placed on creating treatments for kidney diseases. Atrasentan is developed as a selective endothelin A receptor antagonist to lower proteinuria levels in diabetic kidney disease patients. BION-1301 is advanced as an anti-APRIL monoclonal antibody aimed at blocking pathogenic immune complex formation. The company targets unmet needs in renal therapeutics.
- Headquarters Shanghai, China
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website sanreno.com
- Social LinkedIn
- Acquired by Novartis (Jan 2024)
Investors in SanReno
SanReno has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for SanReno
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SanReno
1 people are tracked at SanReno (1 in leadership).
| Name | Role | Group |
|---|---|---|
Haoyu Huang | CEO | Leadership |
Complete people profiles for SanReno
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SanReno
2 dated milestones of SanReno across 3 years, from founding to its latest funding, stage changes and deals.
- Founded SanReno is founded.
- Exit Acquired by Novartis.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sanreno
Complete news archive for SanReno
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SanReno
SanReno was founded in 2021.
SanReno is headquartered in Shanghai, China.
Haoyu Huang is the CEO of SanReno, as recorded in our data.
SanReno was founded in 2021 and is based in Shanghai, China. Operations center on biotechnology, with emphasis placed on creating treatments for kidney diseases. Atrasentan is developed as a selective endothelin A receptor antagonist to lower proteinuria levels in diabetic kidney disease patients. BION-1301 is advanced as an anti-APRIL monoclonal antibody aimed at blocking pathogenic immune complex formation. The company targets unmet needs in renal therapeutics.
SanReno has 1 investor. Key investors include Novartis.
Yes. SanReno was acquired by Novartis in January 2024.